Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards cuts Q3 revenue outlook as heart valve sales hit by EU austerity measures

This article was originally published in Clinica

Executive Summary

Edwards Lifesciences' has lowered its revenue estimate for the third fiscal quarter, as sales of its transcatheter heart valves (THVs) were affected by weakness in the European market. The company is now expecting total sales of $448 million in Q3, compared with previous guidance of $465-485 million. Q3 sales of its THVs, including Sapien, were "below expectations" in Q3 at $124 million globally, and $55 million in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099488

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel